Marie Csete, MD, PhD, ConeSight Therapeutics, Pasadena, CA, describes issues associated with developing cell therapies for ophthalmological conditions. Subretinal delivery of cell therapies require a retinal tear, which can prolong recovery times and even in the case of successful delivery, therapeutic efficacy is not guaranteed. The level of scarring and degeneration in the eye can additionally affect treatment outcomes. Phenotyping patients with visual tests or advanced imaging techniques can address the aforementioned issues by defining a subset of patients who will most likely benefit from cell therapies. This interview took place at Meeting on the Mesa 2021.